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SUMMARY - Thiazolidinediones or glitazones specifically target in-
sulin resistance. They have proven efficacy for reducing plasma glucose
levels of type 2 diabetic patients treated with diet alone, sulphonylureas,
metformin or insulin. In addition, they may be associated to some im-
provement of cardiovascular risk profile. However, troglitazone, the first
compound approved by the FDA in the US, proved to be hepatotoxic and
was withdrawn from the market after the report of several dozens of
deaths or cases of severe hepatic failure requiring liver transplantation.
It remains unclear whether or not hepatotoxicity is a class effect or is
related to the unique tocopherol side chain of troglitazone. Rosiglitazone
and pioglitazone, two other glitazones, appear to have similar efficacy on
blood glucose control of type 2 diabetic patients as compared to troglita-
zone. In controlled clinical trials, the incidence of significant increases in
liver enzyme levels (ALT) was similar with rosiglitazone or pioglitazone as
compared to placebo, whereas troglitazone was associated with a three-
fold greater incidence. In contrast to the numerous case reports of acute
liver failure in patients receiving troglitzone, only two cases of severe
reversible liver failure have been reported in patients treated with rosigli-
tazone, with a causal relationship remaining uncertain. Furthermore, no
single case of severe hepatotoxicity has been reported yet with pioglita-
zone. While regular monitoring of liver enzymes is still recommended and
more long-term data are desirable, current clinical evidence supports the
conclusion that rosiglitazone and pioglitazone do not share the hepato-
toxic profile of troglitazone.
Key-words: hepatitis, liver toxicity, pioglitazone, rosiglitazone,
thiazolidinediones, troglitazone.
RE´SUME´ - Thiazolidinediones et toxicité hépatique.
Les thiazolidinediones, encore appelées glitazones, ont pour cible l’insu-
linorésistance. Elles ont prouvé leur efficacité pour diminuer la glycémie
de patients diabétiques de type 2 traités par régime seul, sulfonylurées,
metformine ou insuline. De plus, elles peuvent améliorer le profil de ris-
que cardio-vasculaire. Cependant, la troglitazone, la première glitazone
acceptée par la FDA aux Etats-Unis, s’est révélée être hépatotoxique et a
dû être retirée du marché après la survenue d’une série de décès ou de
cas d’insuffisance hépatocellulaire terminale requérant une transplanta-
tion. La question de savoir si l’hépatotoxicité est un effet de classe propre
aux glitazones ou si elle est spécifiquement liée à la chaîne latérale de la
troglitazone reste ouverte. La rosiglitazone et la pioglitazone, deux autres
glitazones ont démontré une efficacité sur le contrôle glycémique des
patients diabétiques de type 2 apparemment comparable à celle de la
troglitazone. Dans des essais cliniques contrôlés, l’incidence d’une élé-
vation significative des transaminases hépatiques a été similaire avec la
rosiglitazone ou la pioglitazone par comparaison à celle observée sous
placebo, alors que la troglitazone était associée à une incidence triple.
Au lieu des nombreux cas d’insuffisance hépatique aiguë rapportés sous
troglitzone, seulement deux cas d’hépatotoxicité sévère réversible ont
été décrits avec la rosiglitazone, sans qu’une relation causale ait pu être
définitivement prouvée. Aucun accident de ce type n’a encore été rap-
porté avec la pioglitazone. Bien qu’une surveillance régulière des enzy-
mes hépatiques reste recommandée et que des données complémentai-
res de pharmacovigilance soient certainement souhaitables, l’évidence
clinique actuelle plaide pour la conclusion que ni la rosiglitazone ni la
pioglitazone ne partage le risque d’hépatotoxicité de la troglitazone.
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D ecreased insulin sensitivity is a key de-fect of patients with type 2 diabetes andrepresents a major target for the treat-ment of such patients, especially when
obesity is present [1-3]. Insulin resistance
may not only worsen hyperglycaemia but also may
trigger various metabolic disturbances (arterial hyper-
tension, dyslipidaemias, etc.) that all contribute to
accelerate atherosclerosis and worsen cardiovascular
prognosis [4].
Thiazolidinediones (TZDs) are a new class of oral
antidiabetic agents that directly target insulin resis-
tance [5-10]. Drugs of this class act as ligands for the
gamma subtype of the peroxisome proliferator-
activated receptor (PPAR-γ), which is directly in-
volved in the regulation of genes controlling glucose
homeostasis and lipid metabolism [11, 12]. Troglita-
zone, the first TZD to be approved for clinical use, has
proven effective in reducing glycaemia in patients
with type 2 diabetes [13-17]. Such new insulin sensi-
tizers may not only improve blood glucose control,
but also improve cardiovascular risk profile and pos-
sibly outcome [18, 19].
Clinical development of the TZDs was initially
delayed because of unacceptable poor efficacy or tox-
icity which led to the discontinuation of ciglitazone
and englitazone after the phase II clinical trials [8].
Three compounds, troglitazone [13, 16], rosiglitazone
[20], and pioglitazone [21], appeared to have accept-
able toxicity profiles in clinical trials and were subse-
quently approved by the Food and Drug Administra-
tion in the U.S. The thiazolidine-2-4-dione structure is
common to all drugs of this class, the difference lying
in their side chains which may modify the pharmaco-
logical activity and side effects. Soon after its launch
in 1997, the first available glitazone, troglitazone,
proved to be associated with hepatotoxicity and the
report of several dozens of cases of severe liver failure
and death [22, 23] led to its withdrawal from the US
market in March 2000.
The problem of drug-induced hepatic disorders is a
major concern in pharmacovigilance studies [24, 25].
As liver abnormalities are common in obese subjects,
especially in patients with type 2 diabetes [26-28], it is
important to use strict criteria of drug-induced liver
disorders [29] and to be cautious before considering a
causal relationship between abnormal liver tests and
previous drug administration [30]. The present review
aims at comparing the liver effects of the three main
TZDs, troglitazone, rosiglitazone and pioglitazone, in
order to answer the important question: is hepatotox-
icity a class effect concerning all TZDs or is it specifi-
cally related to troglitazone [31-33]?
m LIVER TOXICITY AND TROGLITAZONE
A few months after its approval in the US for the
treatment of type 2 diabetes in January 1997 [13-17]
and soon after the report of first cases of severe hepa-
totoxicity [22], troglitazone was withdrawn from the
market in the UK (late 1997, i.e. only a few weeks
after its launch) [34]. This was followed by the aban-
donment of the overall approval process and all clini-
cal trials in Europe [35, 36]. In the US and in Japan,
the manufacturer first introduced a series of labelling
changes for troglitazone recommending close moni-
toring of liver enzyme levels and search for clinical
signs of liver dysfunction [37]. Finally, and almost
two years after call to ban troglitazone [38, 39], hepa-
totoxicity led to the withdrawal of the drug in March
2000 [40].
Observations in clinical trials
In early clinical trials with troglitazone, elevations
of serum aminotransferase levels were noted (Fig. 1).
During the combined US trials of troglitazone, 2 510
patients received troglitazone (1 134, i.e. 45% took the
drug for at least 6 months) and 475 received placebo.
Serum ALT was elevated to ≥ 3 × upper limit of nor-
mal range (ULN) in 1.9% (48/2 510) of patients re-
ceiving troglitazone compared with 0.6% (3/475) of
those receiving placebo [22, 32]. Increased ALT led to
discontinuation of treatment in 0.8% (20/2 510) of
troglitazone-treated patients and in no placebo-treated
patients. Of these 20 patients, 12 had peak serum ALT
concentrations ≥ 10 × ULN while five had concentra-
tions ≥ 20 × ULN. Overall, 18 of these patients were
judged by investigators to have significant hepatocel-
lular injury. Liver biopsy performed on two of these
patients was consistent with a hepatocellular drug re-
action and two other patients had additional chole-
static features. Most of the patients with ALT ≥
3 × ULN did not experience symptoms of liver dys-
function and thus were only detected by monitoring
during the clinical trials. Two of 2 510 patients
(0.08%), i.e. two of the 12 with ALT > 10 × ULN,
experienced jaundnice [32]. The onset of the serum
ALT elevations was typically delayed, with only one
patient having an elevation during the first month of
therapy. In most patients, the peak values occurred
between the third and seventh months (mean 147
days; range, 1 to 287). In the 20 patients in whom
therapy was discontinued, serum ALT concentrations
returned to baseline (mean, 55 days; range, 8 to 142)
[22]. In other 20 patients in whom therapy was con-
tinued despite serum ALT levels ≥ 3 × ULN (5 of
whom had ALT ≥ 10 × ULN), ALT values also re-
turned to baseline, indicating that in some patients the
liver is able to adapt to injury associated with trogli-
tazone [22].
Case reports of severe hepatotoxicity
Numerous cases of acute liver failure due to trogli-
tazone appeared in the literature as “case reports” or
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“letters to the Editor” [22, 23, 41-56]. By June 1998,
the FDA had received 560 reports of troglitazone-
related hepatotoxicity, including 24 cases of acute
liver failure. At the time of the FDA Advisory Com-
mittee Meeting in March 1999, 43 cases of acute liver
failure were reported. Nine of these patients received
liver transplantation and a total of 28 had died [32].
On average, they had been on medication for 116 days
(4-236 days); 69% were taking 400 mg/day, 20% were
taking 200 mg/day and 11% were taking 600 mg/day.
This reflects the usual therapeutic dosage distribution
and does not suggest a dose-related effect. At the time
of diagnosis, 89% of the patients had jaundice and in
62% of cases it was the first symptom. Histological
material was available for several of the patients and
showed a consistent pattern of hepatocellular necrosis
with bridging necrosis and fibrosis or collapse [32].
In a systematic analysis of adverse events reported
to the US FDA, Kohlroser et al. [23] reviewed 46
MedWatch reports considered suspicious for hepatitis.
Striking results include the greater than 2: 1 female:
male ratio (suggesting that women may be more sus-
ceptible, even it may also be that more women than
men have taken troglitazone), the marked variability
in cumulative drug dose (1 200-78 000 mg), and
duration of therapy (6-195 days). Most patients had
predominantly hepatocellular or mixed heptocellular-
cholestatic-type injury.
In a series of 35 cases of liver dysfunction in Japan,
elevation of ALT typically occurred within 2 to 5
months of starting troglitazone therapy [57]. Upon
discontinuation of the drug, ALT levels generally de-
clined rapidly, usually to less than half of the ALT
peak level within 4 weeks. Interestingly, total bilirubin
levels at the time of discontinuation of troglitazone
might be a possible prognostic indicator. An investi-
gation by the Ministery of Health and Welfare in
Japan on the side effects of troglitazone showed there
had been 110 cases of liver dysfunction, 7 of which
resulted in death until March 1998 [58]. A character-
istic typical of the patients who died was a rise in the
bilirubin level. In a recent paper, it was stated that in
Japan 153 diabetic patients treated with troglitazone
developed severe hepatitis and 8 of them died of
drug-side effects [59] (Fig. 2).
There is disagreement as to the exact number of
“validated” deaths associated with troglitazone in the
US. The incidence of liver-related death or transplant
appears to average approximately one case in 50 000-
60 000 patients [16, 39]. Focusing specifically on
liver-related deaths, the risk associated with troglita-
zone appears to have steadily declined from 1 in about
40 000 prior to the inclusion of liver enzyme monitor-
FIG. 1. Comparison of the incidence (%) of elevated
alanine aminotransferase (ALT) levels in controlled
clinical trials with troglitazone (TRO, n = 2 510),
rosiglitazone (ROSI, n = 3 314) and pioglitazone
(PIO, n = 1 526) as compared to placebo (PBO).
ULN: upper limit of normal range.
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ing in the product labelling (before October 1997) to
approximately 1 in 100 000 among patients beginning
therapy in 1998, i.e. after the incorporation of a boxed
warning and increased monitoring requirements in the
product labelling [16]. Thus, even if learning to use
troglitazone was helpful [60], reason for concern still
remained [61], and finally the drug was withdrawn
from the US market in March 2000 [40]. By this time,
the FDA had received 61 reports of fatal hepatotoxic-
ity associated with the drug and 7 cases requiring liver
transplantation (Fig. 2).
Cause of troglitazone hepatotoxicity
There have been a few reports of fulminant hepatic
failure in which pathological examinations of the en-
tire liver were made [42, 43, 50]. Extensive histologi-
cal studies may be informative about the mechanism
of the liver failure attributable to troglitazone. The
mechanism of drug-induced liver injury can be classi-
fied into intrinsic (direct toxic) and idiosyncratic [25,
62]. In less severe cases of troglitazone-induced hepa-
titis, liver biopsies were performed in two patients
(including one with jaundice) and demonstrated the
hepatocellular nature of the injury, which was consis-
tent with an idiosyncratic drug reaction [22]. How-
ever, the mechanism of troglitazone-induced fulmi-
nant hepatitis remains obscure. A first autopsy case of
a Japanese diabetic patient treated with troglitazone
who died from fulminant hepatitis indicated that hy-
persensitivity may have played an important role in
the development of liver damage [43]. This assump-
tion was based upon the positive results of a drug-
induced lymphocyte stimulation in vitro test and the
presence of eosinophilic infiltration. In another au-
topsy case of fatal subacute hepatic failure after ad-
ministration of troglitazone, Japanese authors came to
the conclusion that the causative mechanism of liver
dysfunction may be “metabolite aberration, as a result
of accumulation of hepatotoxic metabolite(s), in a
category of idiosyncratic liver injury” [50].
The patients with elevated ALT values after trogli-
tazone did not have fever, rash, or eosinophilia, mak-
ing a classic immune mechanism unlikely [22]. The
hepatotoxicity observed with troglitazone may be re-
lated to its alpha tocopherol side chain which has been
shown to scavenge free radicals in vitro and may have
protective properties against oxidant stress [63]. It is
known, indeed, that the basic quinone structure of
alpha tocopherol is common to other drugs (such ac-
etaminophen) which are subject to CYP2E1-mediated
oxidation reactions forming free radicals which are
hepatotoxic [29]. It is not known whether patients at
risk for troglitazone hepatotoxicity have a polymor-
phism in cytochrome P-450 or other metabolizing
enzyme expression that produces more of a toxic,
highly reactive intermediate.
The use of hepatocyte cultures may be helpful for
the study of hepatotoxicity compounds [64]. Studies
in human and porcine hepatocyte cultures suggested
FIG. 2. Comparison of reported cases (n) of severe hepatitis, liver transplant and death related to troglitazone, rosiglitazone or pioglitazone therapy
in type 2 diabetic patients.
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that the inhibition of troglitazone sulfation may result
in increased hepatotoxicity due to exposure to parent
drug, or increased metabolism by alternate pathways
[65]. Interestingly, studies in rat hepatocyte culture
showed that troglitazone, but not rosiglitazone, is
hepatotoxic, an observation which is in accordance
with clinical experience in humans [66].
Recent information suggested that PPAR-gamma
receptors may be important in control the activation
state of hepatic stellate cells (HSCs) [67]. HSCs rep-
resent the key cellular elements in the liver wound
healing and development of hepatic fibrosis. Upon
liver injury, HSCs acquire the ability to proliferate and
migrate toward the damage areas and increase the
production of extracellular matrix components. In ad-
dition, activated HSCs regulated the recruitment of
inflammatory cells via secretion of chemotactic fac-
tors, including chemokines, and immunomodulatory
cytokines such as interleukin (IL)-10. Activation of
PPAR-gamma such as obtained with troglitazone has
been shown to modulate profibrinogenic and proin-
flammatory actions in HSCs [68]. Thus, although
troglitazone-associated hepatotoxicity is likely to rep-
resent an idiosyncratic reaction in most cases, the
medical community will need to be alert to the possi-
bility that interference with these receptors may cause
hepatic dysfunction [67]. If this is true, caution should
be recommended with all glitazones.
m LIVER TOXICITY AND
ROSIGLITAZONE
The pharmacological and clinical characteristics of
rosiglitazone were extensively reviewed recently [20,
69-71]. Controlled clinical trials have proven its effi-
cacy to improve the blood glucose control of patients
with type 2 diabetes treating with diet alone [72-74],
sulphonylurea [75], metformin [76] or insulin [20].
Rosiglitazone was approved by the FDA and launched
in the US in May 1999. The European Agency for the
Evaluation of Medicinal Products gave its approval in
spring 2000, although with severe restrictions of clini-
cal use: monotherapy and combination with insulin
were excluded and only the combination with either
sulphonylurea or metformin was approved [69].
Observations in clinical trials
In a total of 4 598 diabetic patients who have re-
ceived rosiglitazone in clinical trials (3 314 of them
for six months or more, for a total of 3 673 patient-
years of exposure), the incidence of liver abnormali-
ties (defined as any ALT elevation ≥ 3 × ULN) was
low (0.25%), and similar to that observed in placebo-
treated patients (0.25%) [77] (Fig. 1). Only one pa-
tient on rosiglitazone (0.02%) had a ≥ 10 × ULN el-
evation in ALT compared to 12 patients (0.48%) on
troglitazone [32].
In November 1999, exposure to rosiglitazone in
clinical trials has substantially increased and com-
prised over 5 000 patient years including more than
1 000 patients treated for ≥ 2 years [78]. For all
rosiglitazone-treated patients (including monotherapy
and combination with sulphonylurea or metformin),
the rate of ALT ≥ 3 × ULN is 0.30 cases per 100
patient years, compared to 0.59 cases per 100 patient
years for placebo-treated patients and 0.73 cases per
100 patient years for sulphonylurea- or metformin-
treated patients. Thus, the current clinical trial experi-
ence with rosiglitazone indicates no evidence of
troglitazone-like hepatotoxicity. On the contrary, re-
cent data showed a trend to lower incidence of el-
evated ALT levels in type 2 diabetic patients receiving
rosiglitazone than in those treated with placebo or
other oral antidiabetic agents. This favourable ten-
dency should be confirmed in further studies, but may
be explained by the rosiglitazone-induced reduction of
insulin resistance, a metabolic state which has been
shown to be associated with fatty liver and NASH
[27]. Indeed, a recent study showed that troglitazone
prevents fatty changes of the liver in obese diabetic
rats, presumably by reducing insulin resistance and
improving the metabolic profile [79].
m CASE REPORTS OF HEPATOTOXICITY
Two reports of acute hepatotoxicity attributed to
rosiglitazone appeared in the literature [80, 81]
(Fig. 2). As these two reports are unique, they deserve
further consideration. In a 69-year-old man, after 21
days of rosiglitazone therapy at a daily dose of 4 mg,
severe hepatic failure developed and the patient be-
came comatose [81]. As reported by the Authors, the
patient developed nonspecific symptoms during
rosiglitazone treatment that in retrospect probably re-
flected acute liver injury within one week of the start
of rosiglitazone therapy. The patient was managed
with intensive medical care and he gradually im-
proved over the subsequent two weeks after rosiglita-
zone cessation. Other causes of hepatic failure, such
as viruses and toxins, were excluded. This patient was
also taking verapamil and pravastatin, both of which
can cause hepatitis, but he had been received these
drugs for more than one year without any problem. A
liver biopsy was not performed. It was possible that
ischemic hepatitis (“shock liver”) played a superim-
posed role in this patient’s hepatic dysfunction. How-
ever, according to the Authors, ischemia alone was
unlikely to explain the patient’s initial clinical picture
and the decrease in the serum albumin level which
was associated with the patient’s illness is not typi-
cally associated with shock liver [81]. However, this
interpretation was challenged by three independent
hepatologists whose opinion was asked by Smith
Kline Beecham Pharmaceuticals [82]. They concluded
that this patient’s liver injury was probably the result
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of ischemia and not rosiglitazone. Indeed, the pattern
and time course of biochemical abnormalities were
characteristic of ischemic hepatitis, particularly the
decrease in serum aspartate aminotransferase from
greater than 11 000 U/L to normal within 9 days
(Fig. 3, upper panel). Such high and rapidly normal-
izing serum aminotransferase levels are unusual for
most cases of drug-induced liver disease and have not
been characteristic of troglitazone-induced liver dys-
function [22].
A 61-year-old man receiving rosiglitazone, 4 mg/
day, for 2 weeks presented with anorexia, vomiting,
and abdominal pain [80]. The patient noted the onset
of his symptoms 8 days after starting rosiglitazone
therapy. On admission, liver function tests revealed
severe hepatocellular injury. ALT levels peaked at day
one (1 706 U/L; normal range 0-40) (Fig. 3, lower
panel). Total bilirubin levels remained within the nor-
mal range while direct bilirubin levels were mildly
and transiently elevated. Serum albumin levels were
markedly decreased (minimal value: 2.3 g/L). How-
ever, at no time were signs or symptoms of hepatic
failure observed. Discontinuation of rosiglitazone led
to rapid improvement of liver function and resolution
of symptoms. Serological tests excluded viral hepati-
tis. The patient’s medical history included chronic
obstructive pulmonary disease, a remote history of
alcoholism and intermittent headache. He reported no
recent alcohol intake, but he regularly used acetami-
nophen at a dose of three to four tablets daily before
admission. However, his acetaminophen level on ad-
mission was within the therapeutic range, which made
the diagnosis of acetaminophen toxicity unlikely. The
Authors concluded that liver injury was caused by
rosiglitazone in this patient and probably involved an
idiosyncratic process. They proposed that patients re-
ceiving rosiglitazone should have liver enzyme levels
monitored earlier and more frequently than initially
recommended. However, as pointed out later on [83],
this case was not only clouded by a history of alcohol
abuse and acetaminophen use, but also by concomi-
tant administration of zafirlukast, a compound which
may provoke hepatitis and hyperbilirubinemia and, in
rare cases, hepatic failure and inhibits one of the
metabolic pathways for the clearance of rosiglitazone,
the cytochrome P450 2C9 pathway.
These two reports [80, 81], even if alternative
causes for hepatic failure have been suggested [82, 83]
underline the need for further investigations into the
potential hepatotoxicity of rosiglitazone and other
drugs of the glitazone family. However, after more
than 18 months of commercialization of rosiglitazone
in the US, the number of case reports of rosiglitazone-
related hepatotoxicity remains extremely low, and in-
deed much lower than the corresponding one of
troglitazone-induced cases of liver dysfunction after
the same time interval following launch. It remains
thus unclear whether rosiglitazone per se may be
hepatotoxic in very rare cases or not. What so ever, if
anorexia, fatigue, abdominal pain, nausea, or jaundice
occur with rosiglitazone (especially during the first
few weeks after the initiation of treatment), it is wise
to stop therapy with this agent and to monitor for
hepatic dysfunction. Of course, rosiglitazone therapy
should be discontinued immediately if liver enzyme
levels become elevated.
m LIVER TOXICITY AND PIOGLITAZONE
Well-controlled studies [review in 21, 84, 85] dem-
onstrated that pioglitazone improves blood glucose
profile of type 2 diabetic patients on diet alone [86]
and of patients already receiving sulphonylurea [87],
metformin [88] or insulin [21, 69]. Pioglitazone was
approved by the FDA and commercialized in the US
in July 1999. The European Agency for the Evaluation
of Medicinal Products gave its approval in fall 2000
with the same limitations of use as for rosiglitazone
[69].
FIG. 3. Changes in alanine aminotransferase (ALT) levels in two pa-
tients in whom severe but rapidly reversible hepatotoxicity was attrib-
uted to rosiglitazone (RSG) therapy: case of reference 81 (upper panel)
and case of reference 80 (lower panel).
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Observations in clinical trials
Results from the US placebo-controlled study pro-
gramme showed a total of 4 reports of elevated (≥
3 × ULN) serum levels of ALT after pioglitazone
treatment in 1 526 evaluable patients [89]. This 0.26%
incidence was similar to that observed with placebo,
as two of 793 placebo-treated patients (0.25%) had
elevated serum ALT levels. The proportion of patients
withdrawn from US clinical studies because of abnor-
mal liver function test results was below 0.12% [21].
All patients with follow-up values had reversible el-
evations of ALT. No patient on pioglitazone had a ≥
10 × ULN elevation in ALT compared with 12 patients
(0.48%) on troglitazone (Fig. 1).
The ALT issue in relation with fatty liver or NASH
in patients with type 2 diabetes [26-28] is underscored
by more detailed examination of what happened to
patients in all pioglitazone trials who had elevations ≥
3 × ULN [32]. There were 10 such patients; five had
definite other causes and two were probably due to
other drugs and indeterminate causes (in one the tem-
poral relationship was unknown, in another there was
a chronic elevation of alkaline phosphatase). So, it is
not yet known if any hepatotoxicity occurs with pi-
oglitazone.
Case reports of hepatotoxicity
Until now, no single case of severe liver toxicity
has been reported with pioglitazone despite extensive
use in the US since more than 18 months (Fig. 2).
m CONCLUSIONS
A crucial question is whether liver toxicity recently
reported with troglitazone is related to all glitazones
or whether it may spare rosiglitazone and pioglita-
zone, two other potent members of the TZD family
commercialized in the US in 1999 and approved for
use by the European Agency for the Evaluation of
Medicinal Products in 2000. Even if no obvious hepa-
totoxicity has been demonstrated with these two com-
pounds so far, careful monitoring of liver tests is
recommended at least during the first year of therapy.
However, the observations of a higher NASH-related
prevalence of liver abnormalities in type 2 diabetic
patients highlight the difficulty:
− in selecting diabetic patients which may safely
receive glitazones as it is recommended to exclude
patients with pre-treatment ALT > 2.5 × ULN;
− in interpreting minor elevations of ALT during
treatment, especially when the three-times upper limit
of normal threshold is used as a measure of liver
toxicity. Current recommendations for the use of
rosiglitazone or pioglitazone in type 2 diabetic pa-
tients are to control transaminase liver enzymes before
initiating treatment, then every two months during the
first year of therapy, and at periodic intervals after-
wards. In case of ALT levels > 3 ULN, a new blood
check must be performed rapidly, and the drug must
be stopped immediatedly if such a high value is veri-
fied. Treatment with rosiglitazone or pioglitazone
must also be interrupted in case of jaundnice.
In conclusion, several convincing arguments sug-
gest that hepatoxicity reported with troglitazone,
which led to the withdrawal of this compound from
the market, is specifically related to the side chain of
the molecule rather than to the common thiazolidine-
2-4-dione structure shared by rosiglitazone or piogli-
tazone. While more long-term data are desirable, cur-
rent clinical evidence thus supports the conclusion that
severe hepatotoxicity is not a glitazone class effect.
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